NCT01380184View on ClinicalTrials.gov

Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 5, 2011

Primary Completion Date

October 20, 2011

Study Completion Date

April 5, 2012

Conditions
Cancer, Advanced
Interventions
DRUG

ridaforolimus

4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01380184 - Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059) | Biotech Hunter | Biotech Hunter